Delving deeper into the pathogenesis and genomics of posttransplant diffuse large B-cell lymphoma [0.03%]
深入探究移植后弥漫性大B细胞淋巴瘤的发病机制和基因组学特点
Flore Sneyers,Ana-Lucía Rocha-Iraizos,Vibeke K J Vergote et al.
Flore Sneyers et al.
Posttransplant lymphoproliferative disorders (PTLDs) are a well-known complication of solid organ transplantation and allogeneic hematopoietic stem cell transplantation. The diffuse large B-cell lymphoma subtype (PT-DLBCL) is the most frequ...
Minimal residual disease assessment following CD19-targeted therapy in B-cell precursor acute lymphoblastic leukemia using standardized 12-color flow cytometry: A EuroFlow study [0.03%]
采用国际标准的12色流式细胞术评估CD19靶向治疗后B细胞急性淋巴细胞白血病患者的微小残留病：EuroFlow研究
Martijn W C Verbeek,Michaela Reiterová,Anna Laqua et al.
Martijn W C Verbeek et al.
Detection of minimal/measurable residual disease (MRD) is a critical prognostic marker in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The EuroFlow Consortium previously developed an 8-color flow cytometric MRD protocol, effecti...
Improved post-transplant outcomes since 2000 for Ph-positive acute lymphoblastic leukemia in first remission: A study from the EBMT Acute Leukemia Working Party [0.03%]
Ph阳性急性淋巴细胞白血病首次缓解期患者2000年以来移植后预后的改善：来自欧洲血液和骨髓移植急淋工作组的一项研究
Ali Bazarbachi,Myriam Labopin,Iman Abou Dalle et al.
Ali Bazarbachi et al.
Allogeneic hematopoietic cell transplantation (allo-HCT) remains a curative treatment for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in their first complete remission (CR1). Recent results using th...
Implementation science in hemato-oncology molecular diagnostics in France via the Groupe des Biologistes Moléculaire des Hémopathies Malignes (GBMHM) [0.03%]
法国血液肿瘤分子诊断实施科学——通过血液恶性肿瘤分子生物学家协会（GBMHM）实现
Jean-Michel Cayuela,Pierre Sujobert,Pascale Flandrin-Gresta et al.
Jean-Michel Cayuela et al.
NGS-MRD negativity in post-HSCT ALL spares unnecessary therapeutic interventions triggered by borderline qPCR results without an increase in relapse risk [0.03%]
移植后ALL患者采用NGS-MRD阴性标准可避免qPCR临界值引起的过度治疗而不增加复发风险
Krystof Seferna,Michael Svaton,Andrea Rennerova et al.
Krystof Seferna et al.
Monitoring of minimal residual disease (MRD) after hematopoietic stem cell transplantation (HSCT) in patients with acute lymphoblastic leukemia (ALL) is vital for timely therapeutic intervention planning. However, interpreting low-positive ...
Lukas Müller,Diego Hernando,Moniba Nazeef et al.
Lukas Müller et al.
Editorial
HemaSphere. 2025 Apr 4;9(4):e70122. DOI:10.1002/hem3.70122 2025
Hepatocyte Toll-like receptors contribute to the hepcidin inflammatory response to pathogens and pathogen-derived ligands [0.03%]
肝细胞 toll 样受体参与病原体和病原体衍生配体的hepcidin炎性反应
Katharina Bonitz,Silvia Colucci,Ruiyue Qiu et al.
Katharina Bonitz et al.
Iron restriction is a critical pathomechanism underlying the Anemia of Inflammation and an innate immune response limiting the replication of extracellular pathogens. During infections, innate immune cells detect pathogen-associated molecul...
High-dose therapy followed by autologous stem cell transplantation emerges as the preferred salvage therapy in patients with limited-stage Hodgkin lymphoma progressing/relapsing after initial therapy: A subset analysis of the EORTC/LYSA/FIL H10 trial [0.03%]
高剂量化疗联合自体干细胞移植作为霍奇金淋巴瘤患者初治进展或复发后首选挽救治疗：EORTC/LYSA/FIL H10研究亚组分析结果
Gotti Manuel,Yana Stepanishyna,Tetiana Skrypets et al.
Gotti Manuel et al.
H1-0 is a specific mediator of the repressive ETV6::RUNX1 transcriptional landscape in preleukemia and B cell acute lymphoblastic leukemia [0.03%]
H1-0是特异性介导早幼粒白血病和B细胞急性淋巴细胞白血病的抑制性ETV6::RUNX1染色质表观遗传图的重要介质
Vera H Jepsen,Andrea Hanel,Daniel Picard et al.
Vera H Jepsen et al.
ETV6::RUNX1, the most common oncogenic fusion in pediatric B cell precursor acute lymphoblastic leukemia (BCP-ALL), induces a clinically silent preleukemic state that can persist in carriers for over a decade and may progress to overt leuke...
European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignancies [0.03%]
欧洲肿瘤组织优质肿瘤护理核心要求：血液系统恶性肿瘤
John G Gribben,Leticia Quintanilla-Martinez,Simon Crompton et al.
John G Gribben et al.